Contrafect Announces Publication of Exebacase Phase 2 Study Results in the Journal of Clinical Investigation
17 juin 2020 07h30 HE
|
ContraFect Corporation
Phase 2 study results demonstrated the potential clinical benefit of exebacase, when used in addition to existing antibiotics, for the treatment of life-threatening MRSA bacteremia Exebacase Phase...
MatriSys Bioscience Inc. is pleased to announce that Magda Marquet PhD has been appointed Chairwoman of MatriSys’ Board of Directors
26 mai 2020 12h25 HE
|
MatriSys Bioscience
SAN DIEGO, May 26, 2020 (GLOBE NEWSWIRE) -- MatriSys Bioscience, Inc., a leader in the field of microbiome-based therapeutics, is pleased to announce that Magda Marquet PhD has been appointed...
ContraFect Corporation Announces Private Placement of Common Stock and Warrants to Pfizer Inc.
26 mai 2020 07h30 HE
|
ContraFect Corporation
YONKERS, N.Y., May 26, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on discovering and developing direct lytic agents for the...
ContraFect Corporation Prices Approximately $52.5 Million Public Offering of Common Stock and Warrants
21 mai 2020 22h59 HE
|
ContraFect Corporation
YONKERS, N.Y., May 21, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on discovering and developing direct lytic agents for the...
ContraFect Reports First Quarter 2020 Financial Results and Provides Business Update
15 mai 2020 07h30 HE
|
ContraFect Corporation
YONKERS, N.Y., May 15, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs),...
ContraFect Partners with Leading Orthopedic Center in Europe to Provide Compassionate Use of Exebacase to Patients with Chronic Staphylococcal Prosthetic Joint Infections
13 janv. 2020 08h00 HE
|
ContraFect Corporation
YONKERS, N.Y., Jan. 13, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs),...
ContraFect Announces First Patient Dosed in Pivotal Phase 3 DISRUPT Study of Exebacase as a Treatment for Staph aureus Bacteremia, Including Right-Sided Endocarditis
10 janv. 2020 07h00 HE
|
ContraFect Corporation
YONKERS, N.Y., Jan. 10, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs),...
ContraFect to Present New Data at the 27th European Congress of Clinical Microbiology and Infectious Disease (ECCMID)
19 avr. 2017 07h00 HE
|
ContraFect Corporation
YONKERS, NY--(Marketwired - April 19, 2017) - ContraFect Corporation (NASDAQ: CFRX), a biotechnology company focused on the discovery and development of protein and antibody therapeutics for...
ContraFect Chairman and CEO Steven C. Gilman Takes Temporary Medical Leave
13 mars 2017 07h00 HE
|
ContraFect Corporation
YONKERS, NY--(Marketwired - March 13, 2017) - ContraFect Corporation (NASDAQ: CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody...
ContraFect Provides Program Update
06 janv. 2017 07h00 HE
|
ContraFect Corporation
YONKERS, NY--(Marketwired - January 06, 2017) - ContraFect Corporation (NASDAQ: CFRX) (NASDAQ: CFRXW), a biotechnology company focused on the discovery and development of protein and antibody...